Current Microbiology, Год журнала: 2024, Номер 81(3)
Опубликована: Фев. 5, 2024
Язык: Английский
Rapid Communications in Mass Spectrometry, Год журнала: 2024, Номер 38(18)
Опубликована: Июль 21, 2024
Abstract RATIONALE Conjugation sites are a quality attribute of conjugate vaccines. Proteolysis bioconjugates synthesized by maleimide–thiol chemistry generates type 2 peptides with hydrolyzed thiosuccinimide linker containing information on the conjugation sites. A mass spectrometry (MS)‐cleavable could make identification MS more reliable. METHODS Four synthetic were analyzed matrix‐assisted laser desorption ionization (MALDI) MS/MS and without collision gas. These also partially labeled 18 O in to confirm proposed fragmentation mechanism. vaccine was reduced S ‐alkylated, digested trypsin liquid chromatography–MS/MS using collision‐induced dissociation (CID) higher‐energy collisional (HCD) methods at normalized energy 30. RESULTS metastable preferentially cleaves newly formed pseudopeptide bond within yield P + 71 C 98 ions. ions assignment Partial O‐labeling analysis confirmed structures. CID produces these as two most intense signals favorably than HCD. The latter yields ions, guarantees better sequence coverage promotes other fragmentations linker. CONCLUSIONS Hydrolyzed is cleavable MALDI electrospray gas‐phase fragmentation. resulting fragment (P 98) results be extended self‐hydrolyzing maleimides, which efficiently stabilize upon hydrolysis, antibody–drug conjugates.
Язык: Английский
Процитировано
2
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Апрель 19, 2023
Background Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients must be vaccinated against SARS-CoV-2 as quickly possible after transplantation. The difficulty in obtaining recommended vaccines for allo-HSCT motivated us to utilize an accessible and affordable vaccine with a recombinant receptor-binding domain (RBD)–tetanus toxoid (TT)-conjugated platform shortly the developing country of Iran. Methods This prospective, single-arm study aimed investigate immunogenicity its predictors following three-dose RBD–TT-conjugated regimen administered at 4-week (± 1-week) intervals patients within 3–12 months post allo-HSCT. An immune status ratio (ISR) was measured baseline 4 weeks 1 week) each dose using semiquantitative immunoassay. Using median ISR cut-off point response intensity, we performed logistic regression analysis determine predictive impact several factors on intensity serologic third vaccination dose. Results Thirty-six recipients, mean age 42.42 years time 133 days between start vaccination, were analyzed. Our findings, generalized estimating equation (GEE) model, indicated that, compared 1.55 [95% confidence interval (CI) 0.94 2.17], increased significantly during regimen. reached 2.32 (95% CI 1.84 2.79; p = 0.010) second 3.87 3.25 4.48; 0.001) vaccine, reflecting 69.44% 91.66% seropositivity, respectively. In multivariate analysis, female sex donor [odds (OR) 8.67; 0.028] higher level (OR 3.56; 0.050) two positive strong No serious adverse events (i.e., grades 3 4) observed Conclusions We concluded that early is safe could improve post-allo-HSCT response. further believe pre-allo-HSCT immunization donors may enhance seroconversion who receive entire course first year
Язык: Английский
Процитировано
6
Scandinavian Journal of Immunology, Год журнала: 2023, Номер 99(2)
Опубликована: Дек. 6, 2023
Abstract COVID‐19 disease has plagued the world economy and affected overall well‐being life of most people. Natural infection as well vaccination leads to development an immune response against pathogen. This involves production antibodies, which can neutralize virus during future challenges. In addition, cellular memory with B T cells provides long‐lasting protection. The longevity been a subject intensive research in this field. extent immunity conferred by different forms or natural infections remained debatable for long. Hence, understanding effectiveness these responses among groups people assist government organizations making informed policy decisions. article, based on publicly available data, we have reviewed generated some vaccines SARS‐CoV‐2 its variants, particularly cell individuals.
Язык: Английский
Процитировано
5
Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Авг. 1, 2023
Optimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination. This investigation aimed explore the potential prime-boost COVID-19 vaccination strategies following autologous (auto-) HSCT.In a randomized clinical trial, who had already received two doses receptor-binding domain (RBD) tetanus toxoid (TT) conjugated during three nine months after auto-HSCT were receive either homologous RBD-TT or heterologous inactivated booster dose four weeks course. The outcome was comparing anti-S IgG Immune status ratio (ISR) versus dose. assessment safety and reactogenicity adverse events considered as secondary outcome.Sixty-one recipients recruited randomly assigned mean ISR 3.40 (95% CI: 2.63- 4.16) before with 90.0% seropositive rate. raised 5.12 4.15- 6.08) 100% rate (P= 0.0064) 3.42 2.67- 4.17) 93.0% seropositivity 0.96). In addition, group suffered more AEs dosage than group, but this difference not statistically significant (p = 0.955). multivariable analysis, strategy (heterologous homologous), level dose, length time between positive predictors serologic No serious event attributed vaccination.In primed first year auto-HSCT, platform resulted considerably enhanced non-significantly higher strategy.
Язык: Английский
Процитировано
4
Current Microbiology, Год журнала: 2024, Номер 81(3)
Опубликована: Фев. 5, 2024
Язык: Английский
Процитировано
1